Skip to main content
Log in

Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat

  • Original Articles
  • Cyclophosphamide, Phosphoramide Mustard, Pharmacokinetics, Brain, Plasma, Tumor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

By a sensitive and quantitative fluorometric assay, brain and plasma time-dependent concentration profiles were generated for phosphoramide mustard (PM) and active alkylating metabolites derived from cyclophosphamide (CPA) administration to rats. Whereas PM rapidly disappeared from plasma, with a monophasic half-life of 15.1 min, equimolar administration of CPA generated active metabolites in plasma that disappeared monoexponentially, with a composite half-life of 63 min. As a consequence, the time-dependent concentration integral of active alkylating metabolites derived from CPA administration, calculated between 5 min and infinity, was 3-fold that of PM. Pharmacokinetic parameters were calculated for each compound. The brain/plasma concentration-integral ratios of PM and active alkylating metabolites derived from CPA were 0.18 and 0.20, respectively. The cerebrovascular permeability-surface area product of PM was 7.5×10−5s−1, which is similar to that of other watersoluble anticancer agents that are restricted from entering the brain. The activities of a range of daily doses of PM and CPA were assessed against subcutaneous and intracerebral implants of Walker 256 carcinosarcoma tumor in rats. Inhibition of subcutaneous tumor growth by 50% was caused by CPA and PM doses of 6.6 and 12.0 mg/kg (daily for 5 consecutive days, starting 36 h after tumor implantation), respectively. However, administration of daily doses of up to 40 mg/kg did not significantly increase the survival of animals with intracerebral tumor implants. These studies indicate that active metabolites of CPA are restricted from entering the brain and that only subtherapeutic concentrations are achieved in brain tissue after systemic administration of CPA or PM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CPA:

cyclophosphamide

PM:

phosphoramide mustard

4-HC:

4-hydroxycyclophosphamide

AP:

aldophosphamide

PA:

cerebrovascular permeability-surface area product

References

  1. Allen JC, Helson L (1981) High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55: 749–756

    Google Scholar 

  2. Arndt CAS, Balis FM, McCully CL, Colvin OM, Poplack DG (1988) Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys. Cancer Res 48: 2113–2115

    Google Scholar 

  3. Bielicki L, Voelcker G, Hohorst HJ (1983) Enzymatic toxicogenation of “activated” cyclophosphamide by 3′–5′ exonuclease. J Cancer Res Clin Oncol 105: 27–29

    Google Scholar 

  4. Brock N, Hohorst HJ (1963) Über die Aktivierung von Cyclophosphamide in vivo und in vitro. Arzneimittelforschung 13: 1022–1031

    Google Scholar 

  5. Carter SK, Bakowski MT, Hellmann K (eds) (1987) Chemotherapy of cancer. 3rd ed. Wiley Medical, New York

    Google Scholar 

  6. Colvin M, Padgett CA, Fenselau C (1973) A biologically active metabolite of cyclophosphamide. Cancer Res 33: 915–918

    Google Scholar 

  7. Colvin M, Brundrett RB, Kan M-N, Jardine I, Fenselau C (1976) Alkylating properties of phosphoramide mustard. Cancer Res 36: 1121–1126

    Google Scholar 

  8. Connors TA, Grover PL, McLoughlin AM (1970) Microsomal activation of cyclophosphamide in vivo. Biochem Pharmacol 19: 1533–1535

    Google Scholar 

  9. Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115–129

    Google Scholar 

  10. Cornbleet MA, Leonard RCF, Smyth JF (1984) High-dose alkylating agent therapy: a review of clinical experiences. Cancer Drug Deliv 1: 227–238

    Google Scholar 

  11. Domeyer BE, Sladek NE (1980) Kinetics of cyclophosphamide biotransformation in vivo. Cancer Res 40: 174–180

    Google Scholar 

  12. Dorr R, Fritz W (eds) (1980) Cancer chemotherapy handbook. Kimpton, London

    Google Scholar 

  13. Draeger U, Peter G, Hohorst HJ (1976) Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 60: 355–359

    Google Scholar 

  14. Duncan JH, Colvin OM, Fenselau C (1973) Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicol Appl Pharmacol 24: 317–323

    Google Scholar 

  15. Egorin MJ, Kaplan RS, Salcman M, Aisner J, Colvin M, Wiernik PH, Bachur NR (1982) Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clin Pharmacol Ther 32: 122–128

    Google Scholar 

  16. Engle TW, Zon G, Egan W (1982) [31P]-NMR kinetic studies of the intra- and intermolecular alkylation chemistry of phosphoramide mustard and cognateN-phosphorylated derivatives ofN,N-bis(2-chloroethyl)amine. J Med Chem 25: 1347–1357

    Google Scholar 

  17. Epstein J, Rosenthal RW, Ess RJ (1955) Use ofr-(4-nitrobenzyl)-pyridine as analytical reagent for ethylenimines and alkylating agents. Anal Chem 27: 1435–1439

    Google Scholar 

  18. Finklestein JZ, Tittle K, Meshnik R, Weiner J (1975) Murine neuroblastoma: further evaluation of the C1300 model with single anti-tumor agents. Cancer Chemother Rep 59: 975–983

    Google Scholar 

  19. Foley GE, Friedman OM, Drolet BP (1961) Studies on the mechanism of action of cytoxan-evidence of activation in vivo and in vitro. Cancer Res 21: 57–63

    Google Scholar 

  20. Friedman OM (1967) Studies of some newer phosphoramide mustards. Cancer Chemother Rep 51: 347–357

    Google Scholar 

  21. Friedman OM, Boger E (1961) Chlorimetric estimation of nitrogen mustard in aqueous media. Anal Chem 33: 906–910

    Google Scholar 

  22. Gershwin ME, Goetel EJ, Steinberg AD (1974) Cyclophosphamide: use in practice. Ann Intern Med 80: 531–540

    Google Scholar 

  23. Graul EH, Shaumloffel E, Hundeshagen H, Wilmanns H, Simon G (1967) Metabolism of radioactive cyclophosphamide: animal tests and clinical studies. Cancer 20: 896–899

    Google Scholar 

  24. Greig NH (1987) Optimizing drug delivery to brain tumors. Cancer Treat Rev 14: 1–28

    Google Scholar 

  25. Greig NH (1989) Brain tumors and the blood-tumor barrier. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation. vol 2. clinical studies. Plenum Press, New York, pp 77–106

    Google Scholar 

  26. Greig NH (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification. In: Neuwelt EA (ed) Implications of the blood-brain barrier and its manipulation, vol 1. Basic science aspects. Plenum Press, New York, pp 311–367

    Google Scholar 

  27. Greig NH, Jones H, Cavanagh J (1983) Blood-brain barrier integrity and host responses in experimental metastatic brain tumors. Clin Exp Metastasis 1: 229–246

    Google Scholar 

  28. Greig NH, Sweeney DJ, Rapoport SI (1987) Melphalan concentration-dependent plasma protein binding in healthy humans and rats. Eur J Clin Pharmacol 32: 179–185

    Google Scholar 

  29. Heiss WD, Turnheim M, Mamoli B (1978) Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine. Eur J Cancer 14: 1191–1202

    Google Scholar 

  30. Jardine I, Feneselau C, Kan M-N, Brundrett RB, Colvin M (1978) Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res 38: 408–415

    Google Scholar 

  31. Juma FD, Rogers HJ, Trounce JR, Bradbrook ID (1978) Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1: 229–231

    Google Scholar 

  32. Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209–217

    Google Scholar 

  33. Juma FD, Rogers HJ, Trounce JR (1980) The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. Br J Clin Pharmacol 10: 327–335

    Google Scholar 

  34. Lenssen U, Hohorst HJ (1979) Zur Frage der Permeabilität vonN,N-bis(2-chloräthyl)-Phosphorsäurediamid in Tumorzellen. J Cancer Res Clin Oncol 93: 161–164

    Google Scholar 

  35. Low JE, Boch RF, Sladek NE (1982) Conversion of 4-hydroperoxy-cyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts. Cancer Res 42: 830–837

    Google Scholar 

  36. Miller R (1966) Simultaneous statistical inferences. McGraw-Hill, New York, pp 76–81

    Google Scholar 

  37. Neuwelt E (1989) The blood-brain barrier: does its disruption have a role in the treatment of central nervous system neoplasms? In: Neuwelt E (ed) Implications of the blood-brain barrier and its manipulation. Plenum Press, New York, pp 107–193

    Google Scholar 

  38. Neuwelt EA, Barnett PA, Frenkel EP (1984) Chemotherapeutic agents' permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 14: 154–160

    Google Scholar 

  39. Neuwelt E, Howieson J, Frenkel E, Specht D, Weigel R (1986) Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19: 573–582

    Google Scholar 

  40. Neuwelt E, Dahlborg SA, Goldman D, Dana B, Ramsey FL (1989) Significant prolongation of survival of primary CNS lymphoma patients by combination chemotherapy given in association with osmotic blood-brain barrier disruption. Proc Am Assoc Cancer Res 30: 264

    Google Scholar 

  41. Ninane J, Baurain R, Kraker J de, Ferster A, Trouet A, Cornu G (1989) Alkylating activity in serum, urine and CSF following highdose ifosfamide in children. Cancer Chemother Pharmacol 24 [Suppl]: S2-S6

    Google Scholar 

  42. Nomura K, Watanabe T, Nakamura O, Ohira M, Shibui S, Takakura K, Miki Y (1984) Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas. Neurosurg Rev 7: 13–22

    Google Scholar 

  43. Norpoth K (1969) Untersuchungen zur oxydativen Umsetzung von Endoxan in vivo und in vitro. Habilitationsschrift, Fach Physiologische Chemie, Westfälischen Wilhelms-Universität, Münster

    Google Scholar 

  44. Ohno K, Pettigrew KD, Rapoport SI (1978) Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235: H299-H307

    Google Scholar 

  45. Ohno K, Fredericks WR, Rapoport SI (1979) Osmotic opening of the blood-brain barrier to methotrexate in the rat. Surg Neurol 12: 323–328

    Google Scholar 

  46. Paoletti P, Knerich R, Adinolfi D, Butti G, Pezzotta S (1985) Therapy for central nervous system malignant tumors. In: Gerosa MA, Rosenblum MA, Tridente G (eds) Brain tumors: biopathology and therapy. Pergamon Press, Oxford, pp 223–235 (Advances in the biosciences, vol 58)

    Google Scholar 

  47. Powers JF, Sladek NE (1983) Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats. Cancer Res 43: 1101–1106

    Google Scholar 

  48. Rapoport S (1976) blood-brain barrier in physiology and medicine. Raven Press, New York

    Google Scholar 

  49. Robinson PJ, Rapoport SI (1986) Kinetics of protein binding determine rates of uptake of drugs by brain. Am J Physiol 251: R1212-R1220

    Google Scholar 

  50. Robinson PJ, Rapoport SI (1990) Model for drug uptake by brain tumors: effects of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab 10: 153–161

    Google Scholar 

  51. Sano K, Sato O, Hayakawa I (1966) Adjuvant therapy of brain tumors. Clin Surg 21: 37–46

    Google Scholar 

  52. Shapiro WR (1974) The chemotherapy of intracerebral vs subcutaneous murine gliomas. Arch Neurol 30: 222–226

    Google Scholar 

  53. Shapiro WR, Ausman JI, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: evaluation of BCNU, cyclophosphamide, mithramycin, and methotrexate. Cancer Res 30: 2401–2413

    Google Scholar 

  54. Simon G, Graul EH, Hundeshagen H (1965) Tracer-studien mit radioaktiv markiertem Cyclophosphamid bei Hirntumoren. Acta Neurochir (Wien) 13: 441–456

    Google Scholar 

  55. Sladek NE (1971) Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res 31: 901–908

    Google Scholar 

  56. Sladek NE (1987) Oxazaphosphorines. In: Powis G, Prough RA (eds) Metabolism and action of anti-cancer drugs. Taylor & Fräncis, London, pp 48–90

    Google Scholar 

  57. Sladek NE, Powers JF, Grage GM (1984) Half-life of oxazaphosphorines in biological fluids. Drug Metab Dispos 12: 553–559

    Google Scholar 

  58. Stewart DJ, Russell N, Atack EA, Quarrington A, Stolback L (1984) Cyclophosphamide, doxorubicin, vincristine and dexamethasone in the treatment of bulky CNS lymphoma. J Neuroncol 2: 289

    Google Scholar 

  59. Struck RF, Kirk MC, Witt MH, Laster WR Jr (1975) Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 2: 46–52

    Google Scholar 

  60. Sulings WJ, Struck RF, Wooley CW, Shannon WM (1978) Comparative disposition of phosphoramide mustard and other cyclophosphamide metabolites in the mouse using the salmonella/mutagenesis assay. Cancer Treat Rep 62: 1321–1328

    Google Scholar 

  61. Talha MRZ, Rogers HJ, Trounce JR (1980) Distribution and pharmacokinetics of cyclophosphamide in the rat. Br J Cancer 41: 140–142

    Google Scholar 

  62. Wagner T (1989) Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children — a comment. Cancer Chemother Pharmacol 24 [Suppl]: S7

    Google Scholar 

  63. Yamada R, Kanai N, Hayawaka T, Higashi H, Mogami H, Jinnai D (1968) Experimental studies on chemotherapy of brain tumor. Med J Osaka Univ 18:373–395

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genka, S., Deutsch, J., Stahle, P.L. et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol. 27, 1–7 (1990). https://doi.org/10.1007/BF00689268

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689268

Keywords

Navigation